Leadership Change

Facing financial headwinds, the timeshare giant appoints a new CEO and COO with a bold, performance-based plan to revitalize growth and shareholder value.

Fathom Realty appoints 39-year veteran Stephanie Verderose to a new growth VP role, signaling a strategic focus on agent success in a volatile market.

The confidential sale of Louisiana's iconic Cypress Cove Marina & Lodge signals a hot market for niche real estate, where big money moves behind closed doors.

Lufax names Xiang Ji as its new CEO amid major financial struggles. The move signals a tighter grip from controlling shareholder Ping An Group.

As BRC Inc. preps its 2025 earnings report, can its new energy drink line and veteran mission overcome inflation, lawsuits, and declining margins?

Digital commerce leader Vaimo hires Woody Anderson to lead its enterprise sales, signaling an aggressive strategy to conquer the competitive North American market.

The world's #1 job site appoints former Google VP Jim Giles as its new CTO, signaling a major acceleration of its AI strategy in the HR tech arms race.

Despite public speculation, a new survey shows Capitol Hill aides, especially Republicans, are deeply skeptical of a Trump 2028 bid, citing constitutional barriers.

A global alliance alleges a "drip-drip genocide" of Hindus in Bangladesh, citing a drastic population collapse and escalating violence under recent turmoil.

With a new interim CEO and mounting financial pressure, VERSES AI's upcoming investor webinar is a pivotal test of its bio-inspired AI vision.

Canada's elections commissioner has sanctioned former minister Chrystia Freeland and others for breaking election laws, highlighting ongoing integrity challenges.

With 15+ years on the front lines, new DOMAC leader Monica Trimble plans to elevate the role of dental office managers through national certification.

Nemours Foundation adds Advocate Health's Dr. Betty Chu to its board, a strategic move to leverage her expertise in quality, equity, and large-scale operations.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

As new federal rules banning replacement workers reshape labour disputes, Ottawa has appointed six vice-chairpersons to the heavily burdened CIRB.

In a strategic move, Central Garden & Pet appoints former exec Kay Schwichtenberg to its board, signaling a focus on animal health and institutional knowledge.

With a history of massive contract wins and M&A success, Bob Genter's appointment signals Peraton is doubling down on aggressive growth and operational might.

As Liberty Latin America preps its 2025 results, investors watch to see if strong subscriber growth and cost-cutting can sustain momentum in a competitive market.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.